In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Discover the commercial and brand names of the generic drug Insulin Glargine. This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

(a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee (R) (insulin glargine-yfgn injection) as the first interchangeable biosimilar ...